Salarius Pharmaceuticals, Inc.(SLRX)Earnings, Financials & Key Ratios
SLRX•NASDAQ
$0.74
Price updated May 1, 2026
AboutSalarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.Show more
- Revenue$0
- EBITDA-$6M+55.5%
- Net Income-$6M+55.5%
- EPS (Diluted)-86.85-152268.4%
- ROE-164.02%-2.5%
SLRX Price & Volume
Salarius Pharmaceuticals, Inc. (SLRX) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Threatens Future Operational Continuity
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
Key Thesis Takeaways
- Salarius Pharmaceuticals remains a pre-revenue clinical-stage entity with no commercial product, leaving its valuation entirely dependent on the success of its oncology research pipeline.
- The company faces significant financial headwinds, evidenced by an accumulated deficit of $85.5 million and a consistent reliance on external financing to cover ongoing R&D and SG&A expenses.
- Investors should monitor the company's ability to secure non-dilutive funding, as the current cash burn rate and lack of revenue generation present substantial risks to long-term shareholder value.
Verdict Logic
the company's precarious liquidity position, evidenced by a cash balance of only $4.8 million in 2025Q3 against ongoing operational losses, suggests a high probability of further dilutive financing.
SLRX Growth Metrics
Salarius Pharmaceuticals, Inc. (SLRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-0.22%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM61.9%
Return on Capital
10 Years-94.69%
5 Years-110.52%
3 Years-154.31%
Last Year-168.68%
Peers Comparison
Key metrics vs top competitors for Salarius Pharmaceuticals, Inc. (SLRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.74 | $697.79K | -0.01 | — | — | -164.02% | — | |
| $38.60 | $7.92B | -13.94 | — | — | -68.16% | — | |
| $11.03 | $352.94M | 4.80 | 6774.96% | -256.6% | -17.04% | — | |
| $4.79 | $194.47M | 3.93 | 36.55% | -19.55% | -3.39% | — | |
| $3.41 | $142M | -1002.94 | 10.37% | 52.16% | — | — | |
| $2.28 | $137.53M | -4.07 | — | — | -0% | — |
Compare SLRX vs Peers
Salarius Pharmaceuticals, Inc. (SLRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when SLRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SLRX Frequently Asked Questions
Salarius Pharmaceuticals, Inc. (SLRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is SLRX profitable?
Salarius Pharmaceuticals, Inc. (SLRX) reported a net loss of $5.0M for fiscal year 2024.
Dividend & Returns
What is SLRX's return on equity?
Salarius Pharmaceuticals, Inc. (SLRX) has a return on equity (ROE) of -164.0%. Negative ROE indicates the company is unprofitable.
What is Salarius Pharmaceuticals, Inc.'s free cash flow?
Salarius Pharmaceuticals, Inc. (SLRX) had negative free cash flow of $4.4M in fiscal year 2024, likely due to heavy capital investments.